- Fellowship - Ohio State University Hospital (2006-2009), Hematology Oncology
- Medical School - University of Pittsburgh Graduate School of Public Health (2004-2006), Clinical Research
- Residency - University of Pittsburgh Medical Center (2003-2006), Internal Medicine
- Medical School - Aga Khan University, Pakistan (1996-2001)
Farrukh Awan, M.D.
- Internal Medicine - Hematology/Oncology
- Leukemia Treatment
- Lymphoma Treatment
Farrukh Awan, M.D., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hematology and Oncology at UTSW’s Harold C. Simmons Comprehensive Cancer Center and William P. Clements Jr. University Hospital. He specializes in bone marrow transplantation and treatments for leukemia and lymphoma.
Dr. Awan earned his medical degree at the Aga Khan University Medical College in Pakistan. He completed a residency in internal medicine at the University of Pittsburgh Medical Center and received advanced training in hematology and oncology through a fellowship at The Ohio State University.
Certified by the American Board of Internal Medicine, the American Board of Medical Oncology, and the American Board of Hematology, he joined the UT Southwestern faculty in 2018.
Dr. Awan is a member of several professional organizations, including the American Medical Association, the American Society of Clinical Oncology, and the American Society of Hematology. He is also the recipient of the Young Investigator Award from the American Society of Clinical Oncology and the Clinical Career Development Award from the Lymphoma Research Foundation.
Dr. Awan has delivered scores of presentations, administered multiple grants and clinical trials, and published numerous academic articles and book chapters.
Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.
Guha A, Derbala MH, Zhao Q, Wiczer TE, Woyach JA, Byrd JC, Awan FT, Addison D Journal of the American College of Cardiology 2018 Aug 72 6 697-698
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Rogers KA, Huang Y, Ruppert AS, Awan FT, Heerema NA, Hoffman C, Lozanski G, Maddocks KJ, Moran ME, Reid MA, Lucas M, Woyach JA, Whitlow WT, Jones JA, Byrd JC Blood 2018 Oct 132 15 1568-1572
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, Awan FT, Maddocks K, Andritsos L, Lehman AM, Sampath D, Lapalombella R, Eathiraj S, Abbadessa G, Schwartz B, Johnson AJ, Byrd JC, Woyach JA Cancer discovery 2018 Oct 8 10 1300-1315
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
Awan FT, Thirman MJ, Patel-Donnelly D, Assouline S, Rao AV, Ye W, Hill B, Sharman JP Leukemia & lymphoma 2019 Jan 1-6
-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 May 35 13 1437-1443
Choosing ibrutinib wisely.
Awan FT Blood 2018 Jan 131 2 156-157
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A, Rogers KA, Cheney CM, Mo X, Andritsos LA, Awan FT, Woyach J, Carson WE, Butchar J, Tridandapani S, Hertlein E, Castro CE, Muthusamy N, Byrd JC Blood advances 2019 Feb 3 3 447-460
Use of acalabrutinib in patients with mantle cell lymphoma.
Awan FT, Jurczak W Expert review of hematology 2018 Jun 11 6 495-502
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.
Trnený M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, Lopez A, Awan FT, Montgomery PG, Janikova A, Barbui AM, Sulek K, Terol MJ, Radford J, Guidetti A, Di Nicola M, Siraudin L, Hatteville L, Schwab S, Oprea C, Gianni AM Haematologica 2018 Aug 103 8 1351-1358
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.
Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT Blood advances 2017 Sep 1 20 1739-1748
- Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.
- Leukemia Treatment
- Lymphoma Treatment
- Bone Marrow Transplant
Showing 1 locations